Cargando…
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial
BACKGROUND: CirCe01 trial aimed to assess the clinical utility of circulating tumour cell (CTC)-based monitoring in metastatic breast cancer (MBC) patients beyond the third line of chemotherapy (LC). METHODS: CirCe01 was a prospective, multicentre, randomised trial (NCT01349842) that included patien...
Autores principales: | Cabel, Luc, Berger, Frédérique, Cottu, Paul, Loirat, Delphine, Rampanou, Aurore, Brain, Etienne, Cyrille, Stacy, Bourgeois, Hugues, Kiavue, Nicolas, Deluche, Elise, Ladoire, Sylvain, Campone, Mario, Pierga, Jean-Yves, Bidard, Francois-Clement |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007590/ https://www.ncbi.nlm.nih.gov/pubmed/33473163 http://dx.doi.org/10.1038/s41416-020-01227-3 |
Ejemplares similares
-
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019) -
Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
por: Cabel, Luc, et al.
Publicado: (2020) -
Clinical utility of circulating tumor cells: an update
por: Vasseur, Antoine, et al.
Publicado: (2020) -
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study
por: Alhenc-Gelas, Marion, et al.
Publicado: (2021) -
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study
por: Bidard, François-Clément, et al.
Publicado: (2012)